These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 25943175

  • 1. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
    Kousar S, Wafai ZA, Wani MA, Jan TR, Andrabi KI.
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
    [Abstract] [Full Text] [Related]

  • 2. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
    Chaudhary N, Kabra M, Gulati S, Gupta YK, Pandey RM, Bhatia BD.
    BMC Pediatr; 2016 May 14; 16():66. PubMed ID: 27179628
    [Abstract] [Full Text] [Related]

  • 3. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients.
    Thakkar AN, Bendkhale SR, Taur SR, Gogtay NJ, Thatte UM.
    Neurol India; 2012 May 14; 60(6):577-80. PubMed ID: 23287317
    [Abstract] [Full Text] [Related]

  • 4. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.
    Twardowschy CA, Werneck LC, Scola RH, De Paola L, Silvado CE.
    Arq Neuropsiquiatr; 2011 Apr 14; 69(2A):153-8. PubMed ID: 21537551
    [Abstract] [Full Text] [Related]

  • 5. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Franco V, Perucca E.
    Expert Opin Drug Metab Toxicol; 2015 Apr 14; 11(8):1269-79. PubMed ID: 26037375
    [Abstract] [Full Text] [Related]

  • 6. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients.
    Ramasamy K, Narayan SK, Shewade DG, Chandrasekaran A.
    Ther Drug Monit; 2010 Dec 14; 32(6):762-6. PubMed ID: 21068649
    [Abstract] [Full Text] [Related]

  • 7. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Chang WC, Hung SI, Carleton BC, Chung WH.
    Expert Opin Drug Metab Toxicol; 2020 Aug 14; 16(8):723-734. PubMed ID: 32510242
    [Abstract] [Full Text] [Related]

  • 8. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
    Liao K, Liu Y, Ai CZ, Yu X, Li W.
    Int J Clin Pharmacol Ther; 2018 Jul 14; 56(7):337-346. PubMed ID: 29628024
    [Abstract] [Full Text] [Related]

  • 9. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
    Taur SR, Kulkarni NB, Gandhe PP, Thelma BK, Ravat SH, Gogtay NJ, Thatte UM.
    J Postgrad Med; 2014 Jul 14; 60(3):265-9. PubMed ID: 25121365
    [Abstract] [Full Text] [Related]

  • 10. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, Inui K.
    Clin Pharmacol Ther; 1997 Sep 14; 62(3):287-92. PubMed ID: 9333104
    [Abstract] [Full Text] [Related]

  • 11. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
    Chung WH, Chang WC, Lee YS, Wu YY, Yang CH, Ho HC, Chen MJ, Lin JY, Hui RC, Ho JC, Wu WM, Chen TJ, Wu T, Wu YR, Hsih MS, Tu PH, Chang CN, Hsu CN, Wu TL, Choon SE, Hsu CK, Chen DY, Liu CS, Lin CY, Kaniwa N, Saito Y, Takahashi Y, Nakamura R, Azukizawa H, Shi Y, Wang TH, Chuang SS, Tsai SF, Chang CJ, Chang YS, Hung SI, Taiwan Severe Cutaneous Adverse Reaction Consortium, Japan Pharmacogenomics Data Science Consortium.
    JAMA; 2014 Aug 06; 312(5):525-34. PubMed ID: 25096692
    [Abstract] [Full Text] [Related]

  • 12. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.
    Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, Higuchi S, Otsubo K.
    Clin Pharmacol Ther; 2001 Aug 06; 70(2):175-82. PubMed ID: 11503012
    [Abstract] [Full Text] [Related]

  • 13. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
    Yamamoto Y, Takahashi Y, Nishimura S, Ikumi Y, Mishima N, Kagawa Y.
    Yakugaku Zasshi; 2011 Aug 06; 131(5):809-15. PubMed ID: 21532277
    [Abstract] [Full Text] [Related]

  • 14. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
    Ortega-Vázquez A, Dorado P, Fricke-Galindo I, Jung-Cook H, Monroy-Jaramillo N, Martínez-Juárez IE, Familiar-López I, Peñas-Lledó E, LLerena A, López-López M.
    Pharmacogenomics J; 2016 Jun 06; 16(3):286-92. PubMed ID: 26122019
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study.
    Ebid AH, Ahmed MM, Mohammed SA.
    Ther Drug Monit; 2007 Jun 06; 29(3):305-12. PubMed ID: 17529887
    [Abstract] [Full Text] [Related]

  • 16. The effect of polymorphic metabolism enzymes on serum phenytoin level.
    Ozkaynakci A, Gulcebi MI, Ergeç D, Ulucan K, Uzan M, Ozkara C, Guney I, Onat FY.
    Neurol Sci; 2015 Mar 06; 36(3):397-401. PubMed ID: 25311916
    [Abstract] [Full Text] [Related]

  • 17. Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children.
    Suvichapanich S, Jittikoon J, Wichukchinda N, Kamchaisatian W, Visudtibhan A, Benjapopitak S, Nakornchai S, Manuyakorn W, Mahasirimongkol S.
    J Hum Genet; 2015 Aug 06; 60(8):413-7. PubMed ID: 25994870
    [Abstract] [Full Text] [Related]

  • 18. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
    Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH.
    Ther Drug Monit; 2004 Oct 06; 26(5):534-40. PubMed ID: 15385837
    [Abstract] [Full Text] [Related]

  • 19. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
    van der Weide J, Steijns LS, van Weelden MJ, de Haan K.
    Pharmacogenetics; 2001 Jun 06; 11(4):287-91. PubMed ID: 11434505
    [Abstract] [Full Text] [Related]

  • 20. Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis.
    De T, Christopher R, Nagaraja D.
    Thromb Res; 2014 May 06; 133(5):729-35. PubMed ID: 24530212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.